Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...
TipRanks on MSN22h
Pfizer halts work on hemophilia gene therapy, Nikkei reportsPfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback